Motif Bio Receives Award from Cystic Fibrosis Foundation
Motif Bio® plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has received an award from the Cystic Fibrosis Foundation to fund important in vitro testing that will help to advance the development of iclaprim for the treatment of lung infections in patients with cystic fibrosis (CF). This is the first award that the Company has received from the Cystic Fibrosis Foundation.
David Huang, MD, PhD, Chief Medical Officer of Motif Bio, said: “We are delighted to have received this award from the Cystic Fibrosis Foundation, a leader in the search for a cure for cystic fibrosis. Patients with cystic fibrosis, especially in the later stages of lung disease, are often infected with multidrug resistant bacteria that severely limit treatment options. The grant will advance the work we are doing to further elucidate iclaprim’s ability to inhibit the most problematic bacteria, including multidrug resistant bacteria, that are common in patients with cystic fibrosis.”
Bacterial pathogens that infect the airways of people with CF often exhibit broad-spectrum resistance to currently available antibiotics. Many of these bacteria are inherently resistant to specific classes of antibiotics. Side effects such as nephrotoxicity and peripheral neuropathy have been reported with currently available Gram-positive antibiotics used to treat lung infections in patients with CF. In the in vitro study to be conducted with the $120,000 award from the Cystic Fibrosis Foundation, the activity of iclaprim against various strains of Burkholderia, Stenotrophomonas and Achromobacter will be determined. These bacteria are frequently present in the airways of patients with CF and many strains are resistant to common antibiotics.
Iclaprim has been studied in an animal model of chronic pulmonary methicillin resistant Staphylococcus aureus (MRSA) infection, which mimics the pathophysiology observed in the lungs of patients with CF. These data were published in December 2017 in the European Journal of Clinical Microbiology & Infectious Diseases (Huang, D.B., Morrissey, I., Murphy, T. et al. Eur J Clin Microbiol Infect Dis (2017).
This article has been republished from materials provided by Motif Bio. Note: material may have been edited for length and content. For further information, please contact the cited source.
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
‘Bad’ Antibodies Provide Crucial Protection Against Invading MicrobesNews
In a world first, scientists have revealed how a population of 'bad' antibodies in the immune system - which are usually 'silenced' because they can harm the body - can provide crucial protection against invading microbes.
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
International Conference on Epigenetics and Epitranscriptomics
Sep 17 - Sep 18, 2018